ArticleAdvances in therapy2017
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Article in Advances in therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.Clinical therapeutics · 2021Trial
- Pharmacological management of binge eating disorder.The mental health clinician · 2025Article
- Obesity: assessment and treatment across the care continuum.Annals of medicine · 2025Review
- Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care.Obesity pillars · 2025Review
- Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity.Mayo Clinic proceedings. Innovations, quality & outcomes · 2025Review
- Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.Alpha psychiatry · 2024Review
- Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.Journal of eating disorders · 2023Review
- Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.EClinicalMedicine · 2023Review
- Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors.Psychopharmacology · 2022Article
- Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.Journal of psychopharmacology (Oxford, England) · 2022Review
- What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials.International journal of obesity (2005) · 2022Review
- Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder.Handbook of experimental pharmacology · 2022Review
- Converging vulnerability factors for compulsive food and drug use.Neuropharmacology · 2021Review
- Safety and efficacy of naltrexone for weight loss in adult patients - a systematic review.Archives of medical science : AMS · 2021Review
- Binge Eating Disorder: A 5-Year Retrospective Study on Experimental Drugs.Journal of experimental pharmacology · 2021Review
- The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics.Clinical therapeutics · 2021Review
- Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.Future medicinal chemistry · 2020Review
- The Opioid System and Food Intake: Use of Opiate Antagonists in Treatment of Binge Eating Disorder and Abnormal Eating Behavior.Journal of clinical medicine research · 2020Review
- Development and Validation of the Recognizing Addictive Disorders Scale: A Transdiagnostic Measure of Substance-Related and Other Addictive Disorders.Substance use & misuse · 2020Article
- Bupropion, Alone and in Combination with Naltrexone, Blunts Binge-Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57BL/6J Mice.Alcoholism, clinical and experimental research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBinge eating disorder (BED) is associated with obesity and major depressive disorder (MDD). Naltrexone extended-release (ER)/bupropion ER (NB) is approved as an adjunct to diet and physical activity for chronic weight management. In a prospectively designed 24-week open-label, single-arm, single-site trial of 25 women with MDD and overweight/obesity, NB reduced weight and depressive symptoms.
methodsThis post hoc analysis investigated the relationship between change in self-reported binge eating behavior (evaluated with the Binge Eating Scale [BES]) and changes in weight, control of eating, and depressive symptoms.
resultsAt baseline, 91% of subjects had moderate or severe BES scores, suggesting BED. BES scores were significantly improved from week 4, and by week 24, 83% reported "little or no problem." Improvement in BES scores correlated with improvement in depressive symptoms and control of eating.
conclusionNB may be effective in reducing binge eating symptoms associated with MDD and overweight/obesity. Evaluation of NB in BED appears warranted.
fundingOrexigen Therapeutics, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.